U.S. Markets close in 43 mins
  • S&P 500

    4,406.51
    +52.32 (+1.20%)
     
  • Dow 30

    34,363.21
    +443.37 (+1.31%)
     
  • Nasdaq

    14,917.51
    +171.12 (+1.16%)
     
  • Russell 2000

    2,221.84
    +35.66 (+1.63%)
     
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,770.20
    -8.00 (-0.45%)
     
  • Silver

    23.03
    +0.46 (+2.05%)
     
  • EUR/USD

    1.1701
    -0.0029 (-0.2457%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    22.22
    -2.14 (-8.78%)
     
  • GBP/USD

    1.3633
    -0.0031 (-0.2290%)
     
  • USD/JPY

    109.7900
    +0.5700 (+0.5219%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,083.43
    +42.95 (+4.13%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Nkarta, CRISPR Join Forces On CAR-NK Development For Cancer

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Nkarta Inc (NASDAQ: NKTX) has collaborated with CRISPR Therapeutics AG(NASDAQ: CRSP) to co-develop and commercialize two CAR-NK therapies, in addition to an NK+T program.

  • The companies will split all the R&D costs and any worldwide profits, 50/50.

  • CRISPR and Nkarta will start with a CAR-NK candidate targeting CD70 primarily for oncology indications. The target for their second CAR-NK program has yet to be revealed.

  • In addition to those programs, Nkarta can license CRISPR’s technology to edit five gene targets in an unlimited number of its own NK cell therapies.

  • For each non-collaboration candidate including a gene-editing target licensed from CRISPR, Nkarta will owe the company milestones and royalties on net sales.

  • The agreement includes a three-year exclusivity period between the companies.

  • Price Action: NKTX shares gained 8.96% at $20.18, while CRSP shares are up 2.62% at $110.67 on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.